These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 26137986)

  • 1. Quantitative benefit-harm assessment for setting research priorities: the example of roflumilast for patients with COPD.
    Puhan MA; Yu T; Boyd CM; Ter Riet G
    BMC Med; 2015 Jul; 13():157. PubMed ID: 26137986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease.
    Cazzola M; Calzetta L; Rogliani P; Matera MG
    Expert Opin Drug Discov; 2016 Jul; 11(7):733-44. PubMed ID: 27169612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Novel trends in pharmacotherapy of chronic obstructive pulmonary disease--prevention of exacerbations (focus on roflumilast)].
    Sinopal'nikov AI
    Klin Med (Mosk); 2014; 92(2):57-64. PubMed ID: 25269184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Considerations for Roflumilast: A New Treatment for COPD.
    Kelly Freeman ML
    Consult Pharm; 2012 Mar; 27(3):189-93. PubMed ID: 22421519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Roflumilast in the management of chronic obstructive pulmonary disease.
    Lipari M; Benipal H; Kale-Pradhan P
    Am J Health Syst Pharm; 2013 Dec; 70(23):2087-95. PubMed ID: 24249758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease.
    Hatzelmann A; Morcillo EJ; Lungarella G; Adnot S; Sanjar S; Beume R; Schudt C; Tenor H
    Pulm Pharmacol Ther; 2010 Aug; 23(4):235-56. PubMed ID: 20381629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Roflumilast: doubtful efficacy but clear harms in COPD.
    Prescrire Int; 2013 Jan; 22(134):5-9. PubMed ID: 23367674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of roflumilast in patients with severe COPD and a history of hospitalisation.
    Rabe KF; Calverley PMA; Martinez FJ; Fabbri LM
    Eur Respir J; 2017 Jul; 50(1):. PubMed ID: 28679611
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacokinetic evaluation of roflumilast.
    Lahu G; Nassr N; Hünnemeyer A
    Expert Opin Drug Metab Toxicol; 2011 Dec; 7(12):1577-91. PubMed ID: 22059647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological mechanism of roflumilast in the treatment of asthma-COPD overlap.
    Zhang X; Chen Y; Fan L; Ye J; Fan J; Xu X; You D; Liu S; Chen X; Luo P
    Drug Des Devel Ther; 2018; 12():2371-2379. PubMed ID: 30122895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials.
    Calverley PM; Rabe KF; Goehring UM; Kristiansen S; Fabbri LM; Martinez FJ;
    Lancet; 2009 Aug; 374(9691):685-94. PubMed ID: 19716960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Roflumilast for COPD.
    Izquierdo JL; Aparicio J
    Drugs Today (Barc); 2010 Nov; 46(11):823-31. PubMed ID: 21225021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of roflumilast on chronic obstructive pulmonary disease: a systematic review and meta-analysis.
    Shen LF; Lv XD; Chen WY; Yang Q; Fang ZX; Lu WF
    Ir J Med Sci; 2018 Aug; 187(3):731-738. PubMed ID: 29397527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphodiesterase 4 inhibitors for the treatment of chronic obstructive pulmonary disease: a review of current and developing drugs.
    Mulhall AM; Droege CA; Ernst NE; Panos RJ; Zafar MA
    Expert Opin Investig Drugs; 2015; 24(12):1597-611. PubMed ID: 26419847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design.
    Rennard SI; Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Siddiqui S; Anzueto A; Zhu H
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1921-8. PubMed ID: 27574416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Roflumilast: clinical review of a new option for the treatment of inflammation in COPD].
    Martínez FJ
    Arch Bronconeumol; 2010 Nov; 46 Suppl 9():8-11. PubMed ID: 21320811
    [No Abstract]   [Full Text] [Related]  

  • 17. Roflumilast : the new orally active, selective phophodiesterase-4 inhibitor, for the treatment of COPD.
    Tashkin DP
    Expert Opin Pharmacother; 2014 Jan; 15(1):85-96. PubMed ID: 24032576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of roflumilast in patients with stable chronic obstructive pulmonary disease: a meta-analysis.
    Yan JH; Gu WJ; Pan L
    Pulm Pharmacol Ther; 2014 Feb; 27(1):83-9. PubMed ID: 23624309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How phosphodiesterase 4 inhibitors work in patients with chronic obstructive pulmonary disease of the severe, bronchitic, frequent exacerbator phenotype.
    Giembycz MA; Newton R
    Clin Chest Med; 2014 Mar; 35(1):203-17. PubMed ID: 24507847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Roflumilast inhibits leukocyte-platelet interactions and prevents the prothrombotic functions of polymorphonuclear leukocytes and monocytes.
    Totani L; Amore C; Di Santo A; Dell'Elba G; Piccoli A; Martelli N; Tenor H; Beume R; Evangelista V
    J Thromb Haemost; 2016 Jan; 14(1):191-204. PubMed ID: 26484898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.